Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Chevron Corp (CVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Chevron Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Chevron Corp trades at $176.59 (market cap $346.56B). The key difference: Chevron Corp is far larger — about 77.2× ACADIA Pharmaceuticals Inc.'s market cap, and Chevron Corp pays a 4.09% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CVX | |
|---|---|---|
Market Cap | $4.49B | $346.56B |
Sector | Health | Energy |
52-Week High | $28.06 | $211.14 |
52-Week Low | $20.06 | $146.72 |
Enterprise Value | $3.69B | $386.66B |
Volume | — | 9,807,834 |
Dividend Yield | — | 4.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Chevron (CVX) trades at $168.1, down 0.66% on the day, amid a broader technical bearish signal. The stock shows mixed fundamentals with declining revenue and net income over recent years, though it has consistently beaten earnings expectations. A strong $1.78 dividend is scheduled for payment in June 2026. Wall Street sentiment remains predominantly bullish, with a consensus price target of $209 representing significant upside, countering the current technical weakness.
The investment case balances a high analyst buy rating and attractive dividend against fundamental profit margin compression and exposure to volatile oil prices. Key risks include execution of major projects like the $13.8B Argentina investment and geopolitical tensions affecting supply chains. The stock's current price sits near immediate technical support at $167.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
